Annual Reports & Accounts Yr 31.12.23 now published.20 Feb 2024 20:24
The Annual Reports & Accounts Yr 31.12.23 now published but showing they do not have a 12 month cash runway hence a 28.5% reduction in the SP.All very depressing as they are totally reliant on Duggan digging deep but at 79 how many more years will he want to continue to invest.The following is the note re cash runway:
'Updated Cash Guidance
With the extension of the $100.0 million note, we updated our cash guidance such that we now have sufficient cash to operate into the first quarter of 2025. Our prior cash guidance was to have sufficient funds going into September 2024.'
It is difficult as to what to do but the SP has not been able to go above $5 my son is still invested but Holding.
Extract from Seeking Alpha
'Shares of Summit Therapeutics (NASDAQ:SMMT) plunged 28% in afternoon trading Tuesday after the company released its Q4 earnings report, filed a mixed shelf registration, and disclosed it had extended its cash runway.
Earlier Tuesday, Summit reported a narrowed Q4 adjusted loss of $0.04 per share with no revenue.
The company added that the maturity date for a $100M note from its chairman and CEO, Robert Duggan, had been extended from Sept. 6 to April 1, 2025, thereby extending its cash runway from September 2024 into Q1 2025.
Summit also filed a mixed shelf registration for the potential sale of up to $450M of its securities.'